Rivercell Secures $25M Seed Funding to Revolutionize Drug Discovery with AI

Paris-based biotech startup Rivercell has successfully raised $25 million in a seed funding round aimed at creating an artificial intelligence model that can understand and predict human cell behavior. This innovative venture is positioned to significantly enhance drug discovery processes, addressing a critical challenge in pharmaceutical development.

Rivercell's focus is on building an automated wet lab that will generate high-quality data at scale about how human cells respond to various treatments. The company's approach seeks to close the existing gaps in cellular data, which typically fails to comprehensively account for the complexity of human biology and the variability in treatment responses. By leveraging AI to model these responses, Rivercell aims to provide a more reliable framework for predicting outcomes in drug development.

The funding round, which took place on October 7, 2026, did not announce any specific lead investors, but the capital will be vital for Rivercell as it develops its technology and expands its research capabilities. The startup's distinct approach is anticipated to offer a competitive edge in the crowded biotech space, where other companies are also striving to innovate in drug discovery. Rivercell’s AI-driven model aims to facilitate the identification of effective treatments while minimizing harm to healthy cells, a key concern in therapeutic development.

Rivercell's ambition to create a 'world model' of human cells represents a transformative step forward in biotechnology. As the company embarks on this journey, it will be important to monitor how its developments compare against other emerging technologies in the health tech sector, especially as the demand for more effective drug discovery techniques continues to grow.